RecruitingNot Applicable

Observational Study to Describe Health-Related Quality of Life and Measure Disease Burden Among Patients With Long QT Syndrome Types (LQTS) 2 and 3

United States200 participantsStarted 2025-10-27

Plain-language summary

This is a cross-sectional observational study designed to assess the disease burden and quality of life in individuals with LQTS 2 and 3. Each participant will answer each patient-reported outcome questionnaire only once over a 6-month period. The study will enroll up to 200 participants.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. The participant is willing and provides written informed consent to participate in this study.
✓. Male or female participant of at least 18 years of age, English-speaking.
✓. Confirmed genetic diagnosis of LQT2 or 3, demonstrated by one of the following:
✓. Documented QTc ≥ 480 ms within the last year, demonstrated by one of the following:
✓. The participant is able to operate a smartphone and a companion watch. \*The number of participants with QTc between 480 and 500 ms will be limited to 50.

Exclusion criteria

✕. Current participation in another clinical trial involving a drug or device.
✕. Participants unwilling to use an iPhone or Apple Watch for the duration of the study.
✕. Known diagnosis of Brugada Syndrome
✕. Participants unwilling to comply with outlined procedures.

What they're measuring

Quality of Life (QoL)

Timeframe: Month 1

Quality of Life (QoL)

Timeframe: Month 1

Disease burden

Timeframe: Month 2

Disease burden

Timeframe: month 2

Disease burden

Timeframe: Month 2

Illness perception

Timeframe: Month 3

Illness perception

Timeframe: Month 3

Psychosocial health, including distress, social and psychological well-being, and cardiac-specific measures,

Timeframe: Month 4

Psychosocial health, including distress, social and psychological well-being, and cardiac-specific measures,

Trial details

NCT IDNCT07075445

SponsorThryv Therapeutics, Inc.

Sponsor typeINDUSTRY

Study typeOBSERVATIONAL

Primary completion2026-12-01

Contact for this trial

Study Coordinator

252-955-4157 coordinator@myqtwave.com

View on ClinicalTrials.gov More Long QT Syndrome Type 3 trials

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. The participant is willing and provides written informed consent to participate in this study.
✓. Male or female participant of at least 18 years of age, English-speaking.
✓. Confirmed genetic diagnosis of LQT2 or 3, demonstrated by one of the following:
✓. Documented QTc ≥ 480 ms within the last year, demonstrated by one of the following:
✓. The participant is able to operate a smartphone and a companion watch. \*The number of participants with QTc between 480 and 500 ms will be limited to 50.

Exclusion criteria

✕. Current participation in another clinical trial involving a drug or device.
✕. Participants unwilling to use an iPhone or Apple Watch for the duration of the study.
✕. Known diagnosis of Brugada Syndrome
✕. Participants unwilling to comply with outlined procedures.

What they're measuring

Quality of Life (QoL)

Timeframe: Month 1

Quality of Life (QoL)

Timeframe: Month 1

Disease burden

Timeframe: Month 2

Disease burden

Timeframe: month 2

Disease burden

Timeframe: Month 2

Illness perception

Timeframe: Month 3

Illness perception

Timeframe: Month 3

Psychosocial health, including distress, social and psychological well-being, and cardiac-specific measures,

Timeframe: Month 4

Psychosocial health, including distress, social and psychological well-being, and cardiac-specific measures,